A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Primary Purpose
Colorectal Surgery, Surgical Wound Infection
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
gentamicin-collagen sponge dipped in saline
Sponsored by
About this trial
This is an interventional prevention trial for Colorectal Surgery focused on measuring Colorectal surgery
Eligibility Criteria
Inclusion Criteria:
- Scheduled to undergo nonemergent colon and/or rectal surgical procedures involving a laparotomy incision of at least 7 cm in length or greater. List of eligible procedures: Left Hemicolectomy, Transverse Colectomy, Segmental/Sleeve Left Colon Resection, Total Abdominal Colectomy With Ileorectal Anastomosis, Total Abdominal Colectomy With Ileostomy, Total Abdominal Proctocolectomy (Portion Of Specimen To Be Extracted Via Laparotomy), Low Anterior Resection, Sigmoid Resection, Non-Emergent Hartmann's Procedure, Colotomy With Polypectomy Distal To Hepatic Flexure, Colostomy Takedown Through Laparotomy (Not Peristomal) Incision, Ileo-Pouch Anal Anastomosis, Abdominal Perineal Resection of the Rectum
- Have the capacity to understand and sign an informed consent form.
- Are male or female and > 18 years of age.
- If female, be postmenopausal (no menstrual period for a minimum of 1 year), or surgically sterilized (does not have a uterus or has had bilateral tubal ligation). Females of child-bearing potential must have a negative serum pregnancy test on entry in the study, and agree to use adequate birth control during the study and for 60 days after the administration of study agent.
- Agree to be available for evaluation from baseline until final evaluation at 60 days postsurgery.
Exclusion Criteria:
- Known history of hypersensitivity to gentamicin or bovine collagen.
- Undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). Emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done.
- Undergoing a significant concomitant surgical procedure (e.g., hysterectomy). The following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection).
- Undergoing a laparoscopic, laparoscopic-assisted, or other minimally invasive surgical approach involving a laparotomy incision less than 7 cm.
- History of prior laparotomy within the last 60 days of this planned procedure.
- Planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure.
- Evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that SIRS alone is not an exclusion criterion)
- Current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason.
- Receiving antibiotic therapy within the 1 week prior to the date of surgery.
- Preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin.
- History of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer.
- Recent history of significant drug or alcohol abuse.
- Preoperative prothrombin time (PT) > 1.5 times upper limit of normal
- Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability
- Postsurgical life expectancy ≤ 60 days, in the investigator's or sponsor's opinion.
- Refusal to accept medically indicated blood products.
- Previous participation in this or any other active Innocoll Gentamicin-Collagen Sponge study.
- Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.
- Surgeon does not believe that it will be possible to insert 2 sponges above the fascia in the patient (e.g. in a very thin patient planned to have a small incision)
- Patients with anterior abdominal wall mesh that is not planned to be completely removed during the planned procedure.
- Presence of prosthetic cardiac valve.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
No Intervention
Arm Label
1
2
Arm Description
Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
Standard of care, ie, no gentamicin-collagen sponge.
Outcomes
Primary Outcome Measures
Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 60
Primarily, efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections (involving the laparotomy incision) that occur within the period from surgery through postop day 60.
Secondary Outcome Measures
Number of Participants Who Had Superficial Incisional Surgical Wound Infection
Number of Participants who had superficial incisional surgical wound infection, based on CDC criteria adjudicated by an independent blinded committee
The Effect of the Gentamicin-collagen Sponge on the Proportion of Patients With Deep Incisional Surgical Wound Infection
The proportion of subjects who had deep incisional SWI, based on Centers for Disease Control and Prevention (CDC) criteria adjudicated by an independent blinded committee
The Effect of the Gentamicin-collagen Sponge on the ASEPSIS Score
Mean (SD) ASEPSIS Score Through 60 Days Postoperatively - brief assessment of surgical wound on post-operative Days 3, 4, 5, 6, and 7 (or discharge if earlier) and then questionnaire/phone call on post-operative Days 30 and 60. Score from each time point is added up and the mean score is reported. Used to compare antibiotic regimens for their effectiveness in preventing or treating wound sepsis, well-defined criteria for outcome are needed. A method of assessing wound healing has been devised that defines carefully the characteristics to be considered and how they are to be awarded points. Objective criteria are also included in the assessment. Points are given for the need for Additional treatment, the presence of Serous discharge, Erythema, Purulent exudate, and Separation of the deep tissues, the Isolation of bacteria, and the duration of inpatient Stay (ASEPSIS). The higher the points the worse outcome. Maximum Points would be 60. Minimum points would be 0
The Effect of the Gentamicin-collagen Sponge on Length of Hospital Stay Postoperatively.
Number of Participants Who Were Rehospitalized for Surgical Wound Infection Within 60 Days Post-operatively
The effect of the gentamicin-collagen sponge on rehospitalization for surgical wound infection.
Full Information
NCT ID
NCT00600925
First Posted
January 14, 2008
Last Updated
September 22, 2021
Sponsor
Innocoll
Collaborators
Duke University, Premier Research Group plc
1. Study Identification
Unique Protocol Identification Number
NCT00600925
Brief Title
A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Official Title
A Randomized, Controlled, Phase 3 Study of Gentamicin-Collagen Sponge in General Surgical Subjects at Higher Risk for Surgical Wound Infection
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
March 2009 (Actual)
Study Completion Date
September 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Innocoll
Collaborators
Duke University, Premier Research Group plc
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether the gentamicin-collagen sponge is safe and effective for preventing surgical wound infections in patients undergoing colorectal surgery.
Detailed Description
Surgical wound infection (SWI) is a significant problem in colorectal surgery. Despite the use of routine bowel preparation and prophylactic antibiotics the incidence of SWI is at least 15% in patients undergoing colorectal surgical procedures.Therefore, there is a long unmet need for an intervention that can reduce the incidence and severity of SWIs in patients undergoing colorectal surgery.
Gentamicin is an antibiotic that is effective in treating certain kinds of infection. Collagen is a protein that is found in all mammals. The gentamicin-collagen sponge is a thin flat sponge made out of collagen that comes from cow tendons and containing gentamicin. When inserted into a surgical site, the collagen breaks down and the gentamicin is released at the site but very little is absorbed into the blood stream. The high levels of antibiotic at the surgical site may prevent an infection at the surgical site.
Outside of the United States more than 3,500 subjects have received treatment in clinical studies with the gentamicin-collagen sponge, primarily for orthopedic, intraabdominal, and cardiothoracic surgeries or wound infections following surgical procedures or traumatic events.
In this study, all subjects will be given treatment that is normally given to prevent surgical infections. For subjects randomly assigned to the gentamicin-collagen sponge treatment group, 2 sponges will be inserted into the surgical wound immediately before the surgeon closes it. The control group will receive no collagen sponge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Colorectal Surgery, Surgical Wound Infection
Keywords
Colorectal surgery
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
602 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Insertion of 2 gentamicin-collagen sponges before closure of the laparotomy (each 10 x 10 cm sponge contains 280 mg collagen and 130 mg gentamicin).
Arm Title
2
Arm Type
No Intervention
Arm Description
Standard of care, ie, no gentamicin-collagen sponge.
Intervention Type
Drug
Intervention Name(s)
gentamicin-collagen sponge dipped in saline
Intervention Description
2 gentamicin-collagen sponges inserted before closure of the laparotomy
Primary Outcome Measure Information:
Title
Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 60
Description
Primarily, efficacy will be evaluated by a comparison between the 2 study groups of the incidence of surgical wound infections (involving the laparotomy incision) that occur within the period from surgery through postop day 60.
Time Frame
assessed at Postop Day 1, 2, 3, 7, 30 & 60
Secondary Outcome Measure Information:
Title
Number of Participants Who Had Superficial Incisional Surgical Wound Infection
Description
Number of Participants who had superficial incisional surgical wound infection, based on CDC criteria adjudicated by an independent blinded committee
Time Frame
assessed at Postop Day 1, 2, 3, 7, 30 & 60
Title
The Effect of the Gentamicin-collagen Sponge on the Proportion of Patients With Deep Incisional Surgical Wound Infection
Description
The proportion of subjects who had deep incisional SWI, based on Centers for Disease Control and Prevention (CDC) criteria adjudicated by an independent blinded committee
Time Frame
assessed at Postop Day 1, 2, 3, 7, 30 & 60
Title
The Effect of the Gentamicin-collagen Sponge on the ASEPSIS Score
Description
Mean (SD) ASEPSIS Score Through 60 Days Postoperatively - brief assessment of surgical wound on post-operative Days 3, 4, 5, 6, and 7 (or discharge if earlier) and then questionnaire/phone call on post-operative Days 30 and 60. Score from each time point is added up and the mean score is reported. Used to compare antibiotic regimens for their effectiveness in preventing or treating wound sepsis, well-defined criteria for outcome are needed. A method of assessing wound healing has been devised that defines carefully the characteristics to be considered and how they are to be awarded points. Objective criteria are also included in the assessment. Points are given for the need for Additional treatment, the presence of Serous discharge, Erythema, Purulent exudate, and Separation of the deep tissues, the Isolation of bacteria, and the duration of inpatient Stay (ASEPSIS). The higher the points the worse outcome. Maximum Points would be 60. Minimum points would be 0
Time Frame
Days 3, 4, 5, 6, and 7 (or discharge if earlier) and then questionnaire/phone call on post-operative Days 30 and 60.
Title
The Effect of the Gentamicin-collagen Sponge on Length of Hospital Stay Postoperatively.
Time Frame
Immediate post operative period
Title
Number of Participants Who Were Rehospitalized for Surgical Wound Infection Within 60 Days Post-operatively
Description
The effect of the gentamicin-collagen sponge on rehospitalization for surgical wound infection.
Time Frame
Through 60 days after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Scheduled to undergo nonemergent colon and/or rectal surgical procedures involving a laparotomy incision of at least 7 cm in length or greater. List of eligible procedures: Left Hemicolectomy, Transverse Colectomy, Segmental/Sleeve Left Colon Resection, Total Abdominal Colectomy With Ileorectal Anastomosis, Total Abdominal Colectomy With Ileostomy, Total Abdominal Proctocolectomy (Portion Of Specimen To Be Extracted Via Laparotomy), Low Anterior Resection, Sigmoid Resection, Non-Emergent Hartmann's Procedure, Colotomy With Polypectomy Distal To Hepatic Flexure, Colostomy Takedown Through Laparotomy (Not Peristomal) Incision, Ileo-Pouch Anal Anastomosis, Abdominal Perineal Resection of the Rectum
Have the capacity to understand and sign an informed consent form.
Are male or female and > 18 years of age.
If female, be postmenopausal (no menstrual period for a minimum of 1 year), or surgically sterilized (does not have a uterus or has had bilateral tubal ligation). Females of child-bearing potential must have a negative serum pregnancy test on entry in the study, and agree to use adequate birth control during the study and for 60 days after the administration of study agent.
Agree to be available for evaluation from baseline until final evaluation at 60 days postsurgery.
Exclusion Criteria:
Known history of hypersensitivity to gentamicin or bovine collagen.
Undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). Emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done.
Undergoing a significant concomitant surgical procedure (e.g., hysterectomy). The following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection).
Undergoing a laparoscopic, laparoscopic-assisted, or other minimally invasive surgical approach involving a laparotomy incision less than 7 cm.
History of prior laparotomy within the last 60 days of this planned procedure.
Planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure.
Evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that SIRS alone is not an exclusion criterion)
Current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason.
Receiving antibiotic therapy within the 1 week prior to the date of surgery.
Preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin.
History of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer.
Recent history of significant drug or alcohol abuse.
Preoperative prothrombin time (PT) > 1.5 times upper limit of normal
Pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability
Postsurgical life expectancy ≤ 60 days, in the investigator's or sponsor's opinion.
Refusal to accept medically indicated blood products.
Previous participation in this or any other active Innocoll Gentamicin-Collagen Sponge study.
Participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.
Surgeon does not believe that it will be possible to insert 2 sponges above the fascia in the patient (e.g. in a very thin patient planned to have a small incision)
Patients with anterior abdominal wall mesh that is not planned to be completely removed during the planned procedure.
Presence of prosthetic cardiac valve.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
David Prior
Organizational Affiliation
Innocoll
Official's Role
Study Director
Facility Information:
City
Florence
State/Province
Alabama
Country
United States
City
Mobile
State/Province
Alabama
Country
United States
City
Laguna Hills
State/Province
California
Country
United States
City
Los Angeles
State/Province
California
Country
United States
City
Stanford
State/Province
California
Country
United States
City
Aurora
State/Province
Colorado
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
Tampa
State/Province
Florida
Country
United States
City
Weston
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Indianapolis
State/Province
Indiana
Country
United States
City
Louisville
State/Province
Kentucky
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Baltimore
State/Province
Maryland
Country
United States
City
Detroit
State/Province
Michigan
Country
United States
City
Duluth
State/Province
Minnesota
Country
United States
City
Minneapolis
State/Province
Minnesota
Country
United States
City
Saint Louis
State/Province
Missouri
Country
United States
City
Albany
State/Province
New York
Country
United States
City
Brooklyn
State/Province
New York
Country
United States
City
New York
State/Province
New York
Country
United States
City
Syracuse
State/Province
New York
Country
United States
City
Chapel Hill
State/Province
North Carolina
Country
United States
City
Durham
State/Province
North Carolina
Country
United States
City
Greensboro
State/Province
North Carolina
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Cleveland
State/Province
Ohio
Country
United States
City
Columbus
State/Province
Ohio
Country
United States
City
Oklahoma City
State/Province
Oklahoma
Country
United States
City
Portland
State/Province
Oregon
Country
United States
City
Hershey
State/Province
Pennsylvania
Country
United States
City
Philadelphia
State/Province
Pennsylvania
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Dallas
State/Province
Texas
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Temple
State/Province
Texas
Country
United States
City
Burlington
State/Province
Vermont
Country
United States
City
Seattle
State/Province
Washington
Country
United States
City
Tacoma
State/Province
Washington
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
20825316
Citation
Bennett-Guerrero E, Pappas TN, Koltun WA, Fleshman JW, Lin M, Garg J, Mark DB, Marcet JE, Remzi FH, George VV, Newland K, Corey GR; SWIPE 2 Trial Group. Gentamicin-collagen sponge for infection prophylaxis in colorectal surgery. N Engl J Med. 2010 Sep 9;363(11):1038-49. doi: 10.1056/NEJMoa1000837. Epub 2010 Aug 4. Erratum In: N Engl J Med. 2010 Dec 23;363(26):2573.
Results Reference
derived
Learn more about this trial
A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection
We'll reach out to this number within 24 hrs